Integrated BioPharma can fund operations for 12 months

By Lisa Kerner

Charlotte, N.C., Sept. 27 - Integrated BioPharma, Inc. said it believes its sources of cash will be sufficient to fund company operations and satisfy working capital needs over the next 12 months.

However, if any of Integrated BioPharma's series B preferred shares are outstanding on the maturity date of April 20, 2007, the company will have to convert or redeem the shares, the company said in a 10-K filing with the Securities and Exchange Commission.

The Hillside, N.J., pharmaceutical company can to use its $15.0 million credit facility to redeem the series B preferred shares if necessary.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.